
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Preclinical Pharmacology |
Departments of Medicine [S. H., R. D., Y. D., L. K., G. S., S. G.], Pharmacology [S. G.], Microbiology [L. T., S. G.], Biochemistry [S. G.], and Radiation Oncology [P. D.], Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia 23298
Interactions between the purine analogue 2-fluoroadenine
9-ß-D-arabinofuranoside (F-ara-A) and the kinase
inhibitor UCN-01 have been examined in human leukemia cells (U937 and
HL-60) with respect to induction of mitochondrial damage, caspase
activation, apoptosis, and loss of clonogenic survival. Simultaneous or
subsequent exposure of F-ara-A-treated cells (2 µM) to
UCN-01 (100 nM) resulted in a marked potentiation of
apoptosis, manifested by loss of mitochondrial membrane potential
(
m), cleavage/activation of procaspase-9 and
procaspase-3, DNA fragmentation, and degradation of poly-ADP(ribosyl)
polymerase. Coadministration of UCN-01 with F-ara-A was also associated
with diminished phosphorylation of the cdc25 phosphatase. In contrast,
exposure of cells to the sequence UCN-01, followed by F-ara-A, resulted
in only a modest increase in apoptotic cells. The ability of UCN-01 to
potentiate F-ara-A-mediated lethality was not mimicked by the selective
PKC inhibitor bisindolylmaleimide, nor did treatment of cells with
UCN-01 enhance formation of F-ara-ATP or increase incorporation of
[3H]F-ara-A into DNA. Enhanced apoptosis in cells exposed
sequentially or simultaneously to F-ara-A and UCN-01 was accompanied by
a substantial reduction in colony formation (e.g., to
0.01% of control values). Cotreatment with UCN-01 also increased
F-ara-A-mediated apoptosis and loss of 
m in U937
cells ectopically expressing Bcl-2, although not to the same extent as
that observed in empty-vector controls. Finally, simultaneous exposure
(24 h) of malignant B lymphocytes from the pleural effusion of a
patient with indolent non-Hodgkins lymphoma to F-ara-A and UCN-01
ex vivo resulted in a striking increase in
apoptosis, as determined by terminal
deoxynucleotidyltransferase-mediated nick end labeling assay.
These findings indicate that UCN-01 increases F-ara-A-induced
mitochondrial damage and apoptosis in human leukemia cells in a
sequence-dependent manner, and that these events occur in at least some
primary human lymphoma cells.
This article has been cited by other articles:
![]() |
R. R. Rosato, J. A. Almenara, S. C. Maggio, S. Coe, P. Atadja, P. Dent, and S. Grant Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions Mol. Cancer Ther., October 1, 2008; 7(10): 3285 - 3297. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Rizvi, A. M. Evens, M. S. Tallman, B. P. Nelson, and S. T. Rosen T-cell non-Hodgkin lymphoma Blood, February 15, 2006; 107(4): 1255 - 1264. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Granville, R. M. Memmott, J. J. Gills, and P. A. Dennis Handicapping the Race to Develop Inhibitors of the Phosphoinositide 3-Kinase/Akt/Mammalian Target of Rapamycin Pathway Clin. Cancer Res., February 1, 2006; 12(3): 679 - 689. [Abstract] [Full Text] [PDF] |
||||
![]() |
X.-Y. Pei, Y. Dai, M. Rahmani, W. Li, P. Dent, and S. Grant The Farnesyltransferase Inhibitor L744832 Potentiates UCN-01-Induced Apoptosis in Human Multiple Myeloma Cells Clin. Cancer Res., June 15, 2005; 11(12): 4589 - 4600. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. C. Maggio, R. R. Rosato, L. B. Kramer, Y. Dai, M. Rahmani, D. S. Paik, A. C. Czarnik, S. G. Payne, S. Spiegel, and S. Grant The Histone Deacetylase Inhibitor MS-275 Interacts Synergistically with Fludarabine to Induce Apoptosis in Human Leukemia Cells Cancer Res., April 1, 2004; 64(7): 2590 - 2600. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Rahmani, C. Yu, Y. Dai, E. Reese, W. Ahmed, P. Dent, and S. Grant Coadministration of the Heat Shock Protein 90 Antagonist 17-Allylamino- 17-demethoxygeldanamycin with Suberoylanilide Hydroxamic Acid or Sodium Butyrate Synergistically Induces Apoptosis in Human Leukemia Cells Cancer Res., December 1, 2003; 63(23): 8420 - 8427. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Karp, D. D. Ross, W. Yang, M. L. Tidwell, Y. Wei, J. Greer, D. L. Mann, T. Nakanishi, J. J. Wright, and A. D. Colevas Timed Sequential Therapy of Acute Leukemia with Flavopiridol: In Vitro Model for a Phase I Clinical Trial Clin. Cancer Res., January 1, 2003; 9(1): 307 - 315. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Sampath, Z. Shi, and W. Plunkett Inhibition of Cyclin-Dependent Kinase 2 by the Chk1-Cdc25A Pathway during the S-Phase Checkpoint Activated by Fludarabine: Dysregulation by 7-Hydroxystaurosporine Mol. Pharmacol., September 1, 2002; 62(3): 680 - 688. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Dai, C. Yu, V. Singh, L. Tang, Z. Wang, R. McInistry, P. Dent, and S. Grant Pharmacological Inhibitors of the Mitogen-activated Protein Kinase (MAPK) Kinase/MAPK Cascade Interact Synergistically with UCN-01 to Induce Mitochondrial Dysfunction and Apoptosis in Human Leukemia Cells Cancer Res., July 1, 2001; 61(13): 5106 - 5115. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |